
Lars Fruergaard Jørgensen, CEO of Novo Nordisk, predicts that the company's growth in Denmark will be limited. Instead, he is looking towards the USA. (Archive photo). Photo: Niels Ahlmann Olesen/Ritzau Scanpix
Novo Nordisk sees limits to growth in Denmark
Novo Nordisk’s CEO Lars Fruergaard Jørgensen suggests future growth and investments are likely to shift away from Denmark due to expansion limits. The pharmaceutical giant has a key role in Denmark’s economy, with a significant impact on import figures and tax revenue. Currently, more...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?